|
Segment Reporting – Information by division |
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Merck Serono3 |
Consumer Health3 |
Performance Materials |
Merck Millipore |
Corporate and Other |
Merck Group |
||||||||||||
|
€ million |
Q1 – 2014 |
Q1 – 2013 |
Q1 – 2014 |
Q1 – 2013 |
Q1 – 2014 |
Q1 – 2013 |
Q1 – 2014 |
Q1 – 2013 |
Q1 – 2014 |
Q1 – 2013 |
Q1 – 2014 |
Q1 – 2013 |
||||||
|
||||||||||||||||||
|
Sales |
1,374.9 |
1,388.8 |
180.2 |
181.7 |
402.2 |
421.3 |
656.5 |
668.7 |
– |
– |
2,613.9 |
2,660.4 |
||||||
|
Royalty, license and commission income |
46.2 |
93.3 |
0.3 |
0.1 |
0.5 |
0.8 |
3.9 |
5.8 |
– |
– |
51.0 |
100.1 |
||||||
|
Total revenues |
1,421.1 |
1,482.1 |
180.5 |
181.8 |
402.7 |
422.1 |
660.4 |
674.5 |
– |
– |
2,664.8 |
2,760.5 |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Gross profit |
1,166.8 |
1,251.9 |
120.9 |
124.9 |
246.0 |
265.8 |
395.7 |
394.9 |
–1.1 |
–1.0 |
1,928.3 |
2,036.5 |
||||||
|
Marketing and selling expenses |
–279.8 |
–294.8 |
–68.1 |
–69.1 |
–32.6 |
–35.5 |
–168.6 |
–169.5 |
–0.5 |
0.6 |
–549.5 |
–568.3 |
||||||
|
Royalty, license and commission expenses |
–131.7 |
–131.5 |
0.3 |
–0.7 |
–0.7 |
–0.4 |
–4.1 |
–3.7 |
– |
– |
–136.4 |
–136.3 |
||||||
|
Administration expenses |
–52.2 |
–50.2 |
–6.3 |
–5.8 |
–7.7 |
–7.0 |
–28.6 |
–26.8 |
–37.5 |
–42.9 |
–132.3 |
–132.7 |
||||||
|
Other operating expenses and income |
–26.3 |
–127.7 |
–4.6 |
–6.2 |
–12.6 |
–10.5 |
–19.8 |
–30.8 |
–3.4 |
–8.8 |
–66.8 |
–184.0 |
||||||
|
Research and development costs |
–298.3 |
–322.5 |
–4.8 |
–5.7 |
–37.0 |
–36.4 |
–38.4 |
–41.3 |
–0.4 |
–0.3 |
–378.9 |
–406.2 |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Operating result (EBIT) |
235.8 |
170.2 |
36.7 |
36.8 |
151.7 |
172.5 |
87.0 |
72.3 |
–42.9 |
–52.4 |
468.3 |
399.4 |
||||||
|
Depreciation and amortization |
190.9 |
209.8 |
2.4 |
2.8 |
27.2 |
30.7 |
76.6 |
79.1 |
3.5 |
3.6 |
300.6 |
325.9 |
||||||
|
Impairment losses |
1.3 |
28.3 |
– |
– |
– |
0.1 |
0.1 |
0.1 |
– |
0.1 |
1.4 |
28.6 |
||||||
|
Reversals of impairment losses |
– |
– |
– |
–0.1 |
–0.1 |
– |
– |
– |
– |
– |
–0.1 |
–0.1 |
||||||
|
EBITDA |
428.0 |
408.3 |
39.1 |
39.4 |
178.8 |
203.3 |
163.7 |
151.5 |
–39.4 |
–48.7 |
770.2 |
753.8 |
||||||
|
One-time items |
10.1 |
29.4 |
2.2 |
–0.1 |
7.6 |
4.1 |
5.9 |
10.4 |
11.1 |
3.4 |
36.8 |
47.3 |
||||||
|
EBITDA pre one-time items (Segment result) |
438.0 |
437.7 |
41.3 |
39.3 |
186.4 |
207.4 |
169.7 |
161.9 |
–28.3 |
–45.3 |
807.1 |
801.1 |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
EBITDA margin pre one-time items (% of sales) |
31.9 |
31.5 |
22.9 |
21.6 |
46.3 |
49.2 |
25.8 |
24.2 |
– |
– |
30.9 |
30.1 |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Net operating assets1 |
6,670.8 |
6,890.7 |
346.1 |
335.5 |
1,034.3 |
1,044.7 |
6,017.1 |
5,987.1 |
77.3 |
36.0 |
14,145.5 |
14,294.0 |
||||||
|
Segment liabilities1 |
–1,368.9 |
–1,358.0 |
–96.0 |
–74.5 |
–160.4 |
–155.9 |
–425.3 |
–391.9 |
–48.9 |
–64.8 |
–2,099.5 |
–2,045.1 |
||||||
|
Investments in property, plant and equipment2 |
24.8 |
17.1 |
1.7 |
0.6 |
11.3 |
9.2 |
18.6 |
9.3 |
1.0 |
1.3 |
57.4 |
37.5 |
||||||
|
Investments in intangible assets2 |
2.3 |
25.0 |
1.5 |
– |
0.7 |
0.8 |
1.3 |
1.3 |
2.1 |
1.8 |
7.9 |
28.9 |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Net cash flows from operating activities2 |
446.3 |
332.8 |
30.9 |
22.4 |
167.9 |
203.7 |
99.7 |
106.9 |
–336.0 |
–150.0 |
408.7 |
515.7 |
||||||
|
Business free cash flow |
480.0 |
340.0 |
16.2 |
20.8 |
165.5 |
199.0 |
54.4 |
81.1 |
–31.9 |
–48.1 |
684.1 |
592.9 |
||||||